BlackRock Health Sciences Term Trust (NYSE:BMEZ) Sees Significant Drop in Short Interest

BlackRock Health Sciences Term Trust (NYSE:BMEZ) was the target of a significant drop in short interest in October. As of October 15th, there was short interest totalling 79,800 shares, a drop of 7.4% from the September 30th total of 86,200 shares. Based on an average trading volume of 195,000 shares, the short-interest ratio is presently 0.4 days.

BlackRock Health Sciences Term Trust Trading Down 0.6 %

Shares of BlackRock Health Sciences Term Trust stock traded down 0.09 on Thursday, hitting 15.43. 227,200 shares of the company traded hands, compared to its average volume of 265,695. BlackRock Health Sciences Term Trust has a 12-month low of 12.93 and a 12-month high of 16.59. The company has a 50-day moving average price of 15.83 and a 200 day moving average price of 15.49.

BlackRock Health Sciences Term Trust Announces Dividend

The company also recently disclosed a monthly dividend, which will be paid on Thursday, October 31st. Investors of record on Tuesday, October 15th will be issued a $0.176 dividend. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $2.11 dividend on an annualized basis and a yield of 13.69%.

Insider Transactions at BlackRock Health Sciences Term Trust

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. bought 15,455 shares of BlackRock Health Sciences Term Trust stock in a transaction dated Thursday, September 19th. The stock was bought at an average price of 16.14 per share, for a total transaction of 249,443.70. Following the completion of the acquisition, the insider now directly owns 20,601,568 shares of the company’s stock, valued at approximately 332,509,307.52. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have bought a total of 99,630 shares of company stock valued at $1,585,113 over the last ninety days.

Institutional Investors Weigh In On BlackRock Health Sciences Term Trust

Institutional investors and hedge funds have recently modified their holdings of the business. Dakota Wealth Management lifted its position in shares of BlackRock Health Sciences Term Trust by 5.3% in the second quarter. Dakota Wealth Management now owns 18,242 shares of the company’s stock worth $280,000 after buying an additional 915 shares during the last quarter. Brown Lisle Cummings Inc. boosted its position in BlackRock Health Sciences Term Trust by 6.2% during the third quarter. Brown Lisle Cummings Inc. now owns 36,513 shares of the company’s stock worth $578,000 after purchasing an additional 2,128 shares during the period. Comerica Bank grew its holdings in BlackRock Health Sciences Term Trust by 31.1% during the first quarter. Comerica Bank now owns 15,469 shares of the company’s stock valued at $254,000 after purchasing an additional 3,671 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of BlackRock Health Sciences Term Trust by 4.1% in the first quarter. Commonwealth Equity Services LLC now owns 142,038 shares of the company’s stock valued at $2,328,000 after purchasing an additional 5,537 shares during the period. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in shares of BlackRock Health Sciences Term Trust by 11.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 65,088 shares of the company’s stock worth $1,000,000 after buying an additional 6,565 shares during the last quarter.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.